Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
December 10, 2018 07:10 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018
November 15, 2018 08:30 ET
|
International Stem Cell Corporation
Increases in Revenues and Profit MarginsNet Income Realized for the Quarter CARLSBAD, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO)...
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
November 07, 2018 16:10 ET
|
Voyager Therapeutics, Inc.
One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial Recent preclinical results for Huntington’s disease and...
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
November 07, 2018 16:10 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
November 05, 2018 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based...
Global Kinetics Corporation’s PKG® Smartwatch Provides Clinically Meaningful Improvement in Parkinson’s Disease Symptom Assessment, Management and Medication Optimization, As Well As Projected Per Patient Cost Savings
November 02, 2018 09:00 ET
|
Global Kinetics Corporation
Data Recently Presented at the 2018 International Congress of Parkinson’s Disease and Movement Disorders PORTSMOUTH, N.H., LONDON and MELBOURNE, Australia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Global...
Enable Me Announces Vintage MOTOmed Viva 2 Video Contest in celebration of National Physical Therapy Month; The Most Creative Video About the Classic Viva 2 Wins A New MOTOmed Muvi
October 17, 2018 13:03 ET
|
Enable Me
TAMPA, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Thousands of users of the MOTOmed Viva 2 movement therapy device, first introduced more than a decade ago, have a chance to win an upgrade to the new,...
International Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical Trial
October 08, 2018 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
October 04, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
October 03, 2018 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s...